ELSEVIER

International Journal of Antimicrobial Agents 10 (1998) 325–327

INTERNATIONAL JOURNAL OF
Antimicrobial
Agents

Author index

Volume 10 (1998)

Abeck, D., see Korting, H.C. **10**, 165
Adam, D., see Naber, K.G. **10**, 255
Allerberger, F., see Miglioli, P.A. **10**, 317
Anzani Ciliberti, F., see Fera, M.T. **10**, 285
Aoun, M., F. Crokaert, M. Paesmans, P. Autier and J. Klastersky, Imipenem versus targeted therapy in cancer patients **10**, 263
Araj, G.F., N.K. Daher and Z.A. Tabbarah, Antifungal susceptibility of candida isolates at the American University of Beirut Medical Center **10**, 291
Autier, P., see Aoun, M. **10**, 263

Baann, J., see Bergan, T. **10**, 3
Barquero, A.A., see Castilla, V. **10**, 67
Barquero, A.A., see Castilla, V. **10**, 173
Basile, A., S. Sorbo, S. Giordano, A. Lavitola and R. Castaldo Cobianchi, Antibacterial activity in *Pleurochaete squarrosa* extract (Bryophyta) **10**, 169
Battista De Sarro, G., see Fera, M.T. **10**, 285
Beck, G., see Geiss, H.K. **10**, 237
Berdal, B.P., see Bergan, T. **10**, 3
Berešova, J., see Horváthová, Z. **10**, 55
Bergan, T., P. Gaustad, E.A. Høiby, B.P. Berdal, G. Furuberg, J. Baann and T. Tønjum, Antibiotic resistance of pneumococci in Norway **10**, 3
Blandino, G., see Fera, M.T. **10**, 285
Bland, S., see Mory, F. **10**, 229
Blondeau, J.M., M.E. Suter, S. Borsos and C. Misfeldt, Canadian *Pseudomonas aeruginosa* susceptibility study from 48 medical centers: focus on ciprofloxacin **10**, 297
Borsos, S., see Blondeau, J.M. **10**, 297
Bovill, B., see Minassian, M.A. **10**, 39
Bujdáková, H., A. Laušová, S. Jankovičová, W.M. Prodinger, J. Kallová, P. Milošovič and M. Kettner, Study of β-lactam resistance in ceftazidime-resistant clinical isolates of Enterobacteriaceae **10**, 135

Carbone, M., see Fera, M.T. **10**, 285
Castaldo Cobianchi, R., see Basile, A. **10**, 169
Castilla, V., A.A. Barquero, S.E. Mersich and C.E. Coto, Erratum to "In vitro anti-Junin virus activity of a peptide isolated from *Melia azedarach* L. leaves": [Int. J. Antimicrobial. Agents 10 (1998) 67–75] **10**, 173
Castilla, V., A.A. Barquero, S.E. Mersich and C.E. Coto, In vitro anti-junin virus activity of a peptide isolated from *Melia azedarach* L. leaves **10**, 67
Chang, S.-C., C.-T. Fang, P.-R. Hsueh, C.-J. Liu, W.-H. Sheng, S.-M. Hsieh, C.-C. Hung and Y.-C. Chen, Efficacy and safety of cefepime treatment in Chinese patients with severe bacterial infections: in comparison with ceftazidime treatment **10**, 245
Chattopadhyay, D., see Minassian, M.A. **10**, 39
Chen, Y.-C., see Chang, S.-C. **10**, 245
Chmelík, B., see Horváthová, Z. **10**, 55
Coto, C.E., see Castilla, V. **10**, 67
Coto, C.E., see Castilla, V. **10**, 173
Crokaert, F., see Aoun, M. **10**, 263
Cunha, B.A., Meropenem in elderly and renally impaired patients **10**, 107
Cusumano, V., see Fera, M.T. **10**, 285

Ďačok, J., see Horváthová, Z. **10**, 55
Daher, N.K., see Araj, G.F. **10**, 291
Darouiche, R.O., G. Green and M.D. Mansouri, Antimicrobial activity of antiseptic-coated orthopaedic devices **10**, 83
De Sarro, A., see Fera, M.T. **10**, 285
Dubreuil, L., see Mory, F. **10**, 229
Duckworth, G.J., see Minassian, M.A. **10**, 39

Elena Curti, M., see Periti, P. **10**, 215
Eliopoulos, G.M., see Souli, M. **10**, 23
Emori, M., H. Tomioka, K. Sato and H. Saito, Evaluation of in vivo therapeutic efficacy of a new benzoxazinorifamycin,KRM-1648, in SCID mouse model for disseminated *Mycobacterium avium* complex infection **10**, 59

Fang, C.-T., see Chang, S.-C. **10**, 245
Felmingham, D., see Grüneberg, R.N. **10**, 127
Fera, M.T., M. Carbone, A. De Sarro, G. Blandino, G. Riggio, V. Cusumano, G. Battista De Sarro and F. Anzani Ciliberti, Bactericidal activity of lansoprazole and three macrolides against *Helicobacter pylori* strains tested by the time-kill kinetic method **10**, 285
Freyer, G., B. Ligneau and V. Trillet-Lenoir, Colony-stimulating factors in the prevention of solid tumors induced by chemotherapy in patients with febrile neutropenia **10**, 3
Furuberg, G., see Bergan, T. **10**, 3

Gaustad, P., see Bergan, T. **10**, 3
Geiss, H.K. and G. Beck, Comparative in vitro activity of meropenem versus other routinely used antimicrobials against 18 632 aerobic bacteria tested in 92 German centers **10**, 237
Giordano, S., see Basile, A. **10**, 169
Girard-Pipau, F., see Mory, F. **10**, 229
Green, G., see Darouiche, R.O. **10**, 83
Grollier, G., see Mory, F. **10**, 229
Grüneberg, R.N. and W. Hryniewicz, Clinical relevance of a European collaborative study on comparative susceptibility of Gram-positive clinical isolates to teicoplanin and vancomycin **10**, 271

PII S0924-8579(98)00080-6

Grüneberg, R.N., D. Felmingham, I. Harding, S.B. Shrimpton and A. Nathwani, The Nearchus project: antibiotic susceptibiliy of respiratory pathogens and clinical outcome in lower respiratory tract infections at 27 centres in the UK **10**, 127
Guest, N. and C.E. Langan, Comparison of the efficacy and safety of a short course of ceftibuten with that of amoxycillin/clavulanate in the treatment of acute exacerbations of chronic bronchitis **10**, 49

Hamill, R.J., see Visnegarwala, F. **10**, 191
Hamilton-Miller, J.M.T. and S. Shah, Comparative anti-anaerobic activity of Men 10700, a penem antibiotic **10**, 321
Harding, I., see Grüneberg, R.N. **10**, 127
Hasse, J., see Miglioli, P.A. **10**, 317
Høiby, E.A., see Bergan, T. **10**, 3
Higaki, S., see Morohashi, M. **10**, 251
Hof, H., see Nichterlein, T. **10**, 119
Horváthová, Z., S. Ŝpánik, J. Ŝufliarsky, J. Mardiak, P. Pichňa, E. Pichňova, Ŝ. Krajčík, M. Mráz, B. Chmelík, J. Ďačok, J. Berešova, I. Krúpová, A. Hrachová, J. Trupl, A. Kunová and V. Krčméry, Jr., Bacteremia due to methicillin-resistant staphylococci occurs more frequently in neutropenic patients who received antimicrobial prophylaxis and is associated with higher mortality in comparison to methicillin-sensitive bacteriemia **10**, 55
Hrachová, A., see Horváthová, Z. **10**, 55
Hryniewicz, W., see Grüneberg, R.N. **10**, 271
Hryniewicz, W., T. Zaręba and M. Kawalec, Susceptibility patterns of *Enterococcus* spp. isolated in Poland during 1996 **10**, 303
Hsieh, S.-M., see Chang, S.-C. **10**, 245
Hsueh, P.-R., see Chang, S.-C. **10**, 245
Hung, C.-C., see Chang, S.-C. **10**, 245

Iyer, N.G., see Visnegarwala, F. **10**, 191

Jankovičová, S., see Bujdáková, H. **10**, 135

Kallová, J., see Bujdáková, H. **10**, 135
Kawalec, M., see Hryniewicz, W. **10**, 303
Kettner, M., see Bujdáková, H. **10**, 135
Kimpen, J.L.L., see van Houten, M.A. **10**, 161
Kinzig-Schippers, M., see Well, M. **10**, 31
Klastersky, J., see Aoun, M. **10**, 263
Konorev, M.R., Effect of ranitidine and metronidazole on 1gG activity of patients with *Helicobacter pylori* infection **10**, 249
Korting, H.C., U. Neubert and D. Abeck, Current antimicrobial susceptibility of cutaneous bacteria to first line antibiotics **10**, 165
Krajčík, Ŝ., see Horváthová, Z. **10**, 55
Krčméry, V., Jr., see Horváthová, Z. **10**, 55
Krcmery, V., Jr., see Krupova, Y. **10**, 313
Kretschmar, M., see Nichterlein, T. **10**, 119
Krúpová, I., see Horváthová, Z. **10**, 55
Krupova, Y., J. Novotny, A. Sabo, F. Mateicka and V. Krcmery, Jr., Aetiology, cost of antimicrobial therapy and outcome in neutropenic patients who developed bacteraemia during antimicrobial prophylaxis: a case-control study **10**, 313
Kunová, A., see Horváthová, Z. **10**, 55

Labro, M.-T., Antibacterial agents—phagocytes: new concepts for old in immunomodulation **10**, 11
Lacy, M.K., R.C. Owens, Jr., X. Xu, D.P. Nicolau, R. Quintiliani and C.H. Nightingale, Comparison of bactericidal activity after multidose administration of clarithromycin, azithromycin, and cefuroxime axetil against *Streptococcus pneumoniae* **10**, 279
Langan, C.E., see Guest, N. **10**, 49
Laseur, M., see van Houten, M.A. **10**, 161
Laufen, H., see Nichterlein, T. **10**, 119
Laušová, A., see Bujdáková, H. **10**, 135
Lavitola, A., see Basile, A. **10**, 169
Lewis, D.A., see Minassian, M.A. **10**, 39
Ligneau, B., see Freyer, G. **10**, 3
Liu, C.-J., see Chang, S.-C. **10**, 245
Lozniewski, A., see Mory, F. **10**, 229
Luinge, K., see van Houten, M.A. **10**, 161

Mansouri, M.D., see Darouiche, R.O. **10**, 83
Mardiak, J., see Horváthová, Z. **10**, 55
Mariotti, S.P., see Négrel, A.D. **10**, 259
Mateicka, F., see Krupova, Y. **10**, 313
Mazzei, T., see Periti, P. **10**, 215
Mersich, S.E., see Castilla, V. **10**, 67
Mersich, S.E., see Castilla, V. **10**, 173
Meyer, A., see Nichterlein, T. **10**, 119
Middleton, M. and N. Thatcher, G- and GM-CSF **10**, 91
Miglioli, P.A., F. Allerberger, I. Walderberg and J. Hasse, Antibacterial activity of human pleural fluid: alone and in combination with antibiotics. **10**, 317
Milošovič, P., see Bujdáková, H. **10**, 135
Minassian, M.A., D.A. Lewis, D. Chattopadhyay, B. Bovill, G.J. Duckworth and J.D. Williams, A comparison between single-dose fosfomycin trometamol (Monuril®) and a 5-day course of trimethoprim in the treatment of uncomplicated lower urinary tract infection in women **10**, 39
Misfeldt, C., see Blondeau, J.M. **10**, 297
Morimatsu, S., see Morohashi, M. **10**, 251
Morohashi, M., S. Higaki, S. Morimatsu and T. Yamaagishi, The anti-lipase activity of shiunko on *Propionibacterium acnes* **10**, 251
Mory, F., A. Lozniewski, S. Bland, A. Sedallian, G. Grollier, F. Girard-Pipau, M.F. Paris and L. Dubreuil, Survey of anaerobic susceptibility patterns: A French multicentre study **10**, 229
Mráz, M., see Horváthová, Z. **10**, 55
Mueller-Premru, M. and I. Muzlovic, Typing of consecutive methicillin-resistant *Staphylococcus aureus* isolates from intensive care unit patients and staff with pulsed-field gel electrophoresis **10**, 309
Muzlovic, I., see Mueller-Premru, M. **10**, 309

Naber, K.G. and D. Adam, Classification of fluoroquinolones **10**, 255
Naber, K.G., see Well, M. **10**, 31
Nathwani, A., see Grüneberg, R.N. **10**, 127
Négrel, A.D. and S.P. Mariotti, WHO alliance for the global elimination of blinding trachoma and the potential use of azithromycin **10**, 259
Neubert, U., see Korting, H.C. **10**, 165
Nguyen, C., see Zembower, T.R. **10**, 95
Nichterlein, T., M. Kretschmar, A. Schadt, A. Meyer, A. Wildfeuer, H. Laufen and H. Hof, Reduced intracellular activity of antibiotics against *Listeria monocytogenes* in multidrug resistant cells **10**, 119
Nicolau, D.P., see Lacy, M.K. **10**, 279
Nightingale, C.H., see Lacy, M.K. **10**, 279
Noskin, G.A., see Peterson, L.R. **10**, 207
Noskin, G.A., see Zembower, T.R. **10**, 95
Novotny, J., see Krupova, Y. **10**, 313

Owens, R.C., Jr., see Lacy, M.K. **10**, 279

Paesmans, M., see Aoun, M. **10**, 263
Paris, M.F., see Mory, F. **10**, 229
Periti, P., T. Mazzei and M. Elena Curti, Efficacy and safety of high dose intravenous ciprofloxacin in the treatment of bacterial pneumonia **10**, 215
Peterson, L.R., M. Postelnick, T.L. Pozdol, B. Reisberg and G.A. Noskin, Management of fluoroquinolone resistance in *Pseudomonas aeruginosa*—Outcome of monitored use in a referral hospital **10**, 207

Peterson, L.R., see Zembower, T.R. **10**, 95
Pichňa, P., see Horváthová, Z. **10**, 55
Pichňova, E., see Horváthová, Z. **10**, 55
Postelnick, M.J., see Zembower, T.R. **10**, 95
Postelnick, M., see Peterson, L.R. **10**, 207
Pozdol, T.L., see Peterson, L.R. **10**, 207
Prodinger, W.M., see Bujdáková, H. **10**, 135

Quintiliani, R., see Lacy, M.K. **10**, 279

Raz, P., Urinary tract infection in elderly women **10**, 177
Reisberg, B., see Peterson, L.R. **10**, 207
Riggio, G., see Fera, M.T. **10**, 285
Rotstein, C., see Yip, C. **10**, 181

Sabo, A., see Krupova, Y. **10**, 313
Saito, H., see Emori, M. **10**, 59
Sato, K., see Emori, M. **10**, 59
Schadt, A., see Nichterlein, T. **10**, 119
Schaeffer, A.J., Prostatitis: US perspective **10**, 153
Sedallian, A., see Mory, F. **10**, 229
Shah, S., see Hamilton-Miller, J.M.T. **10**, 321
Sheng, W.-H., see Chang, S.-C. **10**, 245
Shrimpton, S.B., see Grüneberg, R.N. **10**, 127
Sorbo, S., see Basile, A. **10**, 169
Sörgel, F., see Well, M. **10**, 31
Souli, M., C.B. Wennersten and G.M. Eliopoulos, In vitro activity of BAY 12-8039, a new fluoroquinolone, against species representative of respiratory tract pathogens **10**, 23
Ŝpánik, S., see Horváthová, Z. **10**, 55
Ŝufliarsky, J., see Horváthová, Z. **10**, 55
Suter, M.E., see Blondeau, J.M. **10**, 297

Tabbarah, Z.A., see Araj, G.F. **10**, 291
Thatcher, N., see Middleton, M. **10**, 91
Tønjum, T., see Bergan, T. **10**, 3
Tomioka, H., see Emori, M. **10**, 59
Trafny, E.A., Susceptibility of adherent organisms from *Pseudomonas aeruginosa* and *Staphylococcus aureus* strains isolated from burn wounds to antimicrobial agents **10**, 223
Trillet-Lenoir, V., see Freyer, G. **10**, 3
Trupl, J., see Horváthová, Z. **10**, 55

van Houten, M.A., K. Luinge, M. Laseur and J.L.L. Kimpen, Antibiotic utilisation for hospitalised paediatric patients **10**, 161
Visnegarwala, F., N.G. Iyer and R.J. Hamill, Ventilator-associated pneumonia **10**, 191

Walderberg, I., see Miglioli, P.A. **10**, 317
Well, M., K.G. Naber, M. Kinzig-Schippers and F. Sörgel, Urinary bactericidal activity and pharmacokinetics of enoxacin versus norfloxacin and ciprofloxacin in healthy volunteers after a single oral dose **10**, 31
Wennersten, C.B., see Souli, M. **10**, 23
Wiedmann, B., Evaluation of data from susceptibility testing **10**, 89
Wildfeuer, A., see Nichterlein, T. **10**, 119
Williams, J.D., Editorial **10**, 1
Williams, J.D., see Minassian, M.A. **10**, 39
Wilson, A.P.R., Comparative safety of teicoplanin and vancomycin **10**, 143

Xu, X., see Lacy, M.K. **10**, 279

Yamaagishi, T., see Morohashi, M. **10**, 251
Yip, C. and C. Rotstein, Hickman catheter-related infections in patients with cancer **10**, 181

Zaręba, T., see Hryniewicz, W. **10**, 303
Zembower, T.R., G.A. Noskin, M.J. Postelnick, C. Nguyen and L.R. Peterson, The utility of aminoglycosides in an era of emerging drug resistance **10**, 95